PR

Shaping Tomorrow with
Next-Gen Therapeutics
  • home
  • PR
  • Notice

PimedBio Secures U.S. Patent for Novel Drug Candidate
2026-03-25

 

PimedBio Secures U.S. Patent for Novel Drug Candidate  

— Strengthening Corporate Value and Commercial Competitiveness Through Global IP Portfolio Expansion —
(U.S. Patent No. 12583818)

PimedBio, a biopharmaceutical R&D company, is pleased to announce that it has successfully secured a U.S. patent for its innovative drug candidate currently under development. 
This milestone serves as formal recognition of the technology’s novelty and patentability in the world’s largest pharmaceutical market, significantly strengthening the company’s intellectual property (IP) competitiveness and overall corporate value. 

The drug candidate has already been granted patents in major global markets, including Australia, India, China, 17 European countries under the Unitary Patent (UP) system, the United Kingdom, Switzerland, Russia, and Brazil. With the addition of the U.S. patent, PimedBio has established a robust global IP portfolio covering key strategic markets. This portfolio is expected to serve as a critical asset in securing market exclusivity and enhancing leverage in future licensing-out negotiations. 

Furthermore, among the Triadic Patent Families, the application in Japan is currently under examination, while patent processes are also progressing in other regions, including Canada, Mexico, and Spain. These ongoing efforts are expected to further expand the company’s global IP coverage. Such a comprehensive multi-jurisdictional patent strategy strengthens barriers to entry and supports the long-term value and revenue potential of the company’s pipeline. 

By leveraging its proprietary Drugging Informatics™ platform, PimedBio is dedicated to developing differentiated therapeutics for complex diseases. 
This patent achievement is anticipated to enhance the company’s strategic positioning in global partnerships, technology transfer, and co-development opportunities. 
PimedBio will continue to maximize pipeline value through strategic IP expansion and advanced R&D capabilities, driving sustainable growth and delivering long-term value to its stakeholders.

 
LIST